Doximity, Inc.

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: $320M normalized annual FCF base (average of TTM $306.3M and FY2026 $326.5M); 12% FCF growth years 1-5, 7% years 6-10; 9.5% discount rate; 3% terminal growth; $678.1M net cash ($687.8M cash less $9.7M total debt); 182.87M shares outstanding.

Reasoning: Doximity is a highly profitable, asset-light healthcare technology platform with roughly 50% FCF margins, so a standard FCF DCF is appropriate; growth assumptions reflect its double-digit revenue growth trajectory tempered by recently flagged industry growth deceleration.